Cervical Cancer

Updated 28 May 2015

Lowdown on cervical cancer vaccines

Pharmaceutical company MSD launched a vaccine against the cancer-causing human papillomavirus (HPV) this week.

0
Pharmaceutical company MSD launched a vaccine against the cancer-causing human papillomavirus (HPV) this week. This is the second product of its kind to be released in South Africa after the Medicines Control Council (MCC) gave its approval late in February this year.

The first product, launched by GlaxoSmithKline (GSK) in February, protects against HPV types 16 and 18 – which cause cervical cancer.

MSD's product, a quadrivalent recombinant vaccine, also guards against types 16 and 18, but extends protection to include strains 6 and 11 which are responsible for genital warts.

This product is priced at R770 per injection, compared to R700 charged for the GSK product.

Cervical cancer a real threat
Cervical cancer is the main cancer affecting South African women. "One in every 31 women is diagnosed with cervical cancer in her lifetime and it kills over 3 400 women in South Africa each year," says Martha Molete from the Cancer Association of South Africa (CANSA).

According to Molete, the vaccine could save hundreds of thousands of lives and could eradicate cervical cancer in time.

In over 80 percent of cases, cervical cancer is caused by the human papilloma virus (HPV), which is a very common sexually transmitted infection. It is estimated that between 60 and 80 percent of all sexually active individuals may be infected.

Although the strains of HPV that causes cervical cancer (HPV 16 and 18) don't affect men, they are carriers of the disease and can infect their female sexual partners.

The vaccine is already in use in the UK and the US, and is recommended for use in girls and women from the age of 10 upwards.

Cervical cancer - a background
Cervical cancer is a common disease in the developing world. Pap smears are currently the recommended method of screening, according to the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC).

Although it is a preventable disease that is curable if detected and treated in its early stages, it remains the leading cause of cancer-related deaths in South African women, according to the Medical Research Council.

Factors that increase a woman's risk for developing cervical cancer include early sexual activity, multiple sexual partners and smoking.

Read more:
HPV Centre
Cervical Cancer Centre
Genital Warts Centre

April 2008

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules